首页> 外文期刊>Journal of diabetes and its complications >Cellular basis of diabetic nephropathy: V. Endoglin expression levels and diabetic nephropathy risk in patients with Type 1 diabetes.
【24h】

Cellular basis of diabetic nephropathy: V. Endoglin expression levels and diabetic nephropathy risk in patients with Type 1 diabetes.

机译:糖尿病肾病的细胞基础:V. 1型糖尿病患者的内皮糖蛋白表达水平和糖尿病肾病风险。

获取原文
获取原文并翻译 | 示例
           

摘要

Endoglin is an accessory receptor molecule that, in association with transforming growth factor beta (TGF-beta) family receptors Types I and II, binds TGF-beta1, TGF-beta3, activin A, bone morphogenetic protein (BMP)-2 and BMP-7, regulating TGF-beta dependent cellular responses. Relevant to diabetic nephropathy, endoglin, expressed in vascular endothelial and smooth muscle cells, fibroblasts, and mesangial cells, negatively regulates extracellular matrix (ECM). The aim of this study was to evaluate endoglin expression in cultured skin fibroblasts from patients with Type 1 diabetes with and without diabetic nephropathy. Kidney and skin biopsies were performed in 125 Type 1 diabetic patients. The 20 with the fastest rate of mesangial expansion (estimated by electron microscopy) and proteinuria ("fast-track") and the 20 with the slowest rate and normoalbuminuria ("slow-track"), along with 20 controls were studied. Endoglin mRNA expression was assessed by microarray and quantitative real-time polymerase chain reaction (QRT-PCR) and protein expression by Western blot. Age and sex distribution were similar among groups. Diabetes duration was similar (20+/-8 vs. 24+/-7 years), hemoglobin A1c lower (8.4+/-1.2% vs. 9.4+/-1.5%), and glomerular filtration rate higher (115+/-13 vs. 72+/-20 ml/min per 1.73 m2) in slow-track vs. fast-track patients. Microarray endoglin mRNA expression levels were higher in slow-track (1516.0+/-349.9) than fast-track (1211.0+/-274.9; P=.008) patients or controls (1223.1+/-422.9; P=.018). This was confirmed by QRT-PCR. Endoglin protein expression levels correlated with microarray (r=0.59; P=.044) and QRTPCR (r=0.61; P=.034) endoglin mRNA expression. These studies are compatible with the hypothesis that slow-track Type 1 diabetic patients, strongly protected from diabetic nephropathy, have distinct cellular behaviors that may be associated with reduced ECM production.
机译:内皮糖蛋白是一种辅助受体分子,与I型和II型转化生长因子β(TGF-beta)家族受体结合,结合TGF-beta1,TGF-beta3,激活素A,骨形态发生蛋白(BMP)-2和BMP- 7,调节TGF-β依赖性细胞应答。与糖尿病肾病相关的内皮糖蛋白在血管内皮和平滑肌细胞,成纤维细胞和肾小球膜细胞中表达,对细胞外基质(ECM)产生负调节作用。这项研究的目的是评估在患有和不患有糖尿病肾病的1型糖尿病患者中培养的皮肤成纤维细胞中内皮糖蛋白的表达。在125名1型糖尿病患者中进行了肾脏和皮肤活检。研究了肾小球系膜扩张速度最快的20个(通过电子显微镜估计)和蛋白尿(“快速通道”),以及肾小球系膜扩张最快的20个和正常白蛋白尿(“慢通道”),以及20个对照。通过微阵列和定量实时聚合酶链反应(QRT-PCR)评估内皮糖蛋白mRNA的表达,并通过蛋白质印迹法评估蛋白质的表达。各组之间的年龄和性别分布相似。糖尿病持续时间相似(20 +/- 8 vs. 24 +/- 7岁),血红蛋白A1c降低(8.4 +/- 1.2%vs. 9.4 +/- 1.5%),肾小球滤过率更高(115 +/-慢轨和快轨患者分别为13 vs. 72 +/- 20 ml / min / 1.73 m2)。微阵列内皮糖蛋白mRNA表达水平在慢轨道(1516.0 +/- 349.9)中高于快速轨道(1211.0 +/- 274.9; P = .008)患者或对照(1223.1 +/- 422.9; P = .018)。 QRT-PCR证实了这一点。内皮糖蛋白蛋白表达水平与微阵列(r = 0.59; P = .044)和QRTPCR(r = 0.61; P = .034)内皮糖蛋白mRNA表达相关。这些研究与以下假设相吻合:慢通道的1型糖尿病患者受到糖尿病肾病的强烈保护,具有独特的细胞行为,可能与ECM产生减少有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号